海特生物：CAR-T联合用药前景向好 将全力对劲新药商业化进程

Core Viewpoint - The event "Enhancing Quality and Efficiency to Strengthen Confidence, Seeking Stability to Promote Development" was successfully held, focusing on the 2025 investor reception day and the 2024 annual performance briefing for listed companies in Hubei [1] Company Summary - Hite Bio (300683) discussed the market promotion progress of its key product, Epunaimab, during an investor interaction session, highlighting its unique mechanism of action targeting DR4 and DR5, which differs from existing anti-tumor drugs [3] - The company noted that preclinical studies indicate that Epunaimab may positively influence the expansion of CAR-T cells in patients receiving CAR-T cell therapy by affecting the immune microenvironment [3] - Epunaimab is increasingly being integrated into mainstream blood disease hospitals' CAR-T treatment processes in China, with collaborations ongoing with leading hospitals such as the Chinese Academy of Medical Sciences Blood Disease Hospital and the Western Theater Command General Hospital for clinical trials [3] - The company plans to intensify efforts in the commercialization of new drugs, focusing resources on advancing the market launch and sales of Epunaimab to increase its market share [3]